Payment overview · 2025
General Payments
$223.08
12 reported records · 7 companies
Healthcare provider profile · identity verified
David M. Andres, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · SENECA, PA · NPI 1235132630
Verified facts
What the public records show
CMS Open Payments records show David M. Andres, D.O. received $223.08 in general payments during 2025 across 12 reported records.
ABBVIE INC. accounted for 35.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $78.67 | 35.3% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $39.39 | 17.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.70 | 14.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.56 | 9.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.94 | 8.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.42 | 7.4% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $15.40 | 6.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $223.08 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $59.31 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $59.31 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $39.39 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $31.70 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.56 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.56 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.94 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.42 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $15.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 154 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 76 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 65 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
62 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
154 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
76 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
125 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 443 | 122 |
| Atorvastatin Calcium | Atorvastatin Calcium | 394 | 120 |
| Levothyroxine Sodium | Levothyroxine Sodium | 325 | 89 |
| Omeprazole | Omeprazole | 315 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 291 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 290 | 81 |
| Pravastatin Sodium | Pravastatin Sodium | 246 | 69 |
| Metformin Hcl | Metformin Hcl | 207 | 63 |
| Jardiance | Empagliflozin | 189 | 40 |
| Potassium Chloride | Potassium Chloride | 176 | 58 |
| Gabapentin | Gabapentin | 160 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 157 | 46 |
| Ozempic | Semaglutide | 154 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 153 | 47 |
| Carvedilol | Carvedilol | 152 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 151 | 47 |
| Alendronate Sodium | Alendronate Sodium | 125 | 34 |
| Eliquis | Apixaban | 125 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 125 | 36 |
| Spironolactone | Spironolactone | 115 | 34 |
| Furosemide | Furosemide | 112 | 41 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 107 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 103 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 102 | 26 |
| Meloxicam | Meloxicam | 99 | 36 |
| Montelukast Sodium | Montelukast Sodium | 94 | 26 |
| Prednisone | Prednisone | 93 | 60 |
| Atenolol | Atenolol | 92 | 27 |
| Warfarin Sodium | Warfarin Sodium | 92 | 18 |
| Allopurinol | Allopurinol | 89 | 25 |
| Glimepiride | Glimepiride | 84 | 30 |
| Losartan Potassium | Losartan Potassium | 84 | 31 |
| Doxycycline Hyclate | Doxycycline Hyclate | 81 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 41 |
| Metformin Hcl Er | Metformin Hcl | 79 | 25 |
| Rybelsus | Semaglutide | 76 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 76 | 23 |
| Sertraline Hcl | Sertraline Hcl | 74 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 22 |
| Valsartan | Valsartan | 72 | 22 |
| Simvastatin | Simvastatin | 68 | 18 |
| Famotidine | Famotidine | 67 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 65 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 65 | suppressed |
| Trulicity | Dulaglutide | 63 | 12 |
| Synthroid | Levothyroxine Sodium | 62 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 20 |
| Mounjaro | Tirzepatide | 58 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 58 | 21 |
| Baclofen | Baclofen | 57 | 15 |
| Nifedipine Er | Nifedipine | 54 | 15 |
| Trazodone Hcl | Trazodone Hcl | 53 | 12 |
| Amoxicillin | Amoxicillin | 52 | 36 |
| Colchicine | Colchicine | 52 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 50 | 25 |
| Xarelto | Rivaroxaban | 49 | 11 |
| Mirtazapine | Mirtazapine | 48 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | 12 |
| Methenamine Hippurate | Methenamine Hippurate | 45 | 11 |
| Celecoxib | Celecoxib | 44 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 43 | 15 |
| Labetalol Hcl | Labetalol Hcl | 43 | 12 |
| Irbesartan | Irbesartan | 42 | 12 |
| Donepezil Hcl | Donepezil Hcl | 41 | 12 |
| Ezetimibe | Ezetimibe | 41 | suppressed |
| Lorazepam | Lorazepam | 40 | 17 |
| Tradjenta | Linagliptin | 39 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 13 |
| Finasteride | Finasteride | 35 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | 11 |
| Topiramate | Topiramate | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 30 | 18 |
| Azelastine Hcl | Azelastine Hcl | 29 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 14 |
| Raloxifene Hcl | Raloxifene Hcl | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Alprazolam | Alprazolam | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 12 |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 14 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $223.08 · 12 records | ABBVIE INC. | ACCRUFER, Cologuard Collection Kit, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error